Ari Melnick
Affiliations: | Weill Cornell Medicine |
Area:
Cancer EpigeneticsGoogle:
"Ari Melnick"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Portelinha A, Wang S, Parsa S, et al. (2024) SETD1B mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma. The Journal of Experimental Medicine. 221 |
Li J, Chin CR, Ying HY, et al. (2024) Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nature Communications. 15: 2879 |
Deng Q, Lakra P, Gou P, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer Cell |
Barisic D, Chin CR, Meydan C, et al. (2024) ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis. Cancer Cell |
Safa FM, Rasmussen T, Fontan L, et al. (2023) Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application. Haematologica |
Shah SB, Carlson CR, Lai K, et al. (2023) Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas. Nature Materials |
Leca J, Lemonnier F, Meydan C, et al. (2023) IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer Cell |
Mlynarczyk C, Teater M, Pae J, et al. (2023) mutation yields supercompetitive B cells primed for malignant transformation. Science (New York, N.Y.). 379: eabj7412 |
Fortin J, Chiang MF, Meydan C, et al. (2023) Distinct and opposite effects of leukemogenic and mutations in hematopoietic stem and progenitor cells. Proceedings of the National Academy of Sciences of the United States of America. 120: e2208176120 |
Flumann R, Hansen J, Pelzer BW, et al. (2022) Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies. Blood Cancer Discovery |